Neuroleptic malignant syndrome due to risperidone misdiagnosed as status epileptics

Ali Ertug Arslankoylu, Meryem Ozlem Kutuk, Cetin Okuyaz, Fevziye Toros
Mersin University Faculty of Medicine, Department of Pediatrics, Pediatric Intensive Care Unit, Mersin, Turkey

Abstract

Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal disease characterized by fever, muscle rigidity, delirium and autonomic instability. Here we report a child, with NMS due to the risperidone misdiagnosed as status epilepticus. Nine year old boy, who had been under high dose risperidone treatment for 8 weeks, admitted to the emergency room because of the contractions (evaluated as status epilepticus) persisting for 7 hours. Since there was neuroleptic treatment in the past medical history and, unconsciousness, muscular rigidity, diaphoresis, hypertermia and, hypotension in physical examination, leukocytosis and elevated creatinin phosphokinase levels in laboratory tests, the patient was evaluated as NMS and discharged without any complications. We reported this case to point out that; NMS may be misdiagnosed as status epilepticus in children when EEG monitoring is unavailable. When a child admitted to the emergency room because of suspicious convolution neuroleptic drug use must surely be asked.

Case Report

Nine years old boy was admitted to the emergency department because of the convulsions persisting for seven hours. He had attention deficit hyperactivity disorder and he had been under risperidone (2 x 2 mg/day) treatment orally for 8 weeks because of moderate mental retardation and psychological disorder. Risperidone dose was four times more than usually recommended pediatric dosage. Additionally the patient had been suffering vomiting, tremor and fever for two weeks.

Physical examination in the emergency room revealed a body temperature of 39°C, a respiratory rate of 10 breaths/min, and, a pulse rate of 158 beats/min. Blood pressure was too low that it couldn’t be measured initially. The patient’s general appearance was lethargic. There was muscular rigidity, tremor and, diaphoresis. He was dehydrated. Heart sounds were rhythmic and tachycardic. His respiration was weak and respiratory sounds were normal. Bilateral pupil reflexes were positive. Deep tendon reflexes were brisk and bilateral Babinski reflexes were positive. There were no meningal irritation signs.

Initial laboratory analysis revealed a white blood cell count of 21580 cells/mm³, with 2% band neutrophils, 62% neutrophils, 30% lymphocytes, 6% monocytes. Serum electrolytes were in normal ranges included a sodium level of 136 mEq/L; potassium, 5.4 mEq/L; chloride 105 mEq/L and, calcium 8.2 mEq/L. The blood glucose was 316 mg/dL. Initial venous blood gases showed a pH of 7.04; carbon dioxide tension 95 mmHg; bicarbonate 26 mEq/L and, base excess, -5.8 mmol/L. The serum creatinine phosphokinase (CPK) level was 1658 U/L. Blood, urine and stool cultures were negative. Urinalysis, chest radiograph, cranial CT and EEG were unremarkable.

Although the tremors accompany muscular rigidity were mimicking convulsions and the patient was admitted with status epilepticus diagnosis, the patient was not diagnosed as status epilepticus because there were neuroleptic treatment in his medical history, muscular rigidity, diaphoresis, hypertermia and hypotension in physical examination, leukocytosis and elevated CPK levels in laboratory tests. By the help of the sign and symptoms above, the patient was diagnosed as NMS by pediatric critical care intensivist, pediatric neurologist and pediatric psychiatrist. NMS diagnosis was confirmed with EEG and risperidone treatment was ceased.

In the emergency department the patient was entubated because of respiratory failure. Then he was admitted to the pediatric intensive care unit and mechanically ventilated. Intravenous diazepam infusion (0.3 mg/kg hour) and carbidopa/levodopa were given for NMS treatment. In the first day of the admission to the intensive care unit the patient had hyperthermia resistant to the antipyretic treatment and his blood pressure was unstable. Central venous catheter was placed and hemodynamic parameters of the patient were regulated in normal ranges. In the second day of the admission to the intensive care unit the patient was extubated. All the clinical and laboratory signs and symptoms of the patient improved except elevated creatinin phosphokinase levels which turned back to normal values on the fifth day of the admission. Then he was discharged from the hospital without complications.
Here we report a patient with NMS who was misdiagnosed as status epilepticus before admission to our hospital. Our patient was diagnosed as NMS due to presence of mentioned criteria of NMS. Mortality rate of NMS in the patients without specific treatment is approximately 21%. Mortality rate may be higher in patients with misdiagnosis. NMS signs and symptoms may be difficult to differentiate from status epilepticus by inexperienced physicians when EEG monitoring is unavailable. As mentioned before, our patient was diagnosed as status epilepticus before he was admitted to our hospital and he had been tried to be treated as status epilepticus at the beginning.

The clinical signs and symptoms of our patient emerged in the second week of the risperidone treatment. As it was pointed out before NMS may occur in anytime during neuroleptic treatment. First step of the NMS treatment is to cease antipsychotic drugs. After we diagnosed NMS we discontinued the risperidone treatment. Cooler blankets and antipyretics for hyperthermia and supportive treatment including fluid electrolyte therapy must be supplied. In medical treatment in order to reduce muscular rigidity dopamine agonists are used. Similarly we used dopamine agonists for our patient. Additionally dantrolene may be used alone or with dopamine.

Previously it was thought that NMS was only associated with the use of classical neuroleptics. However there are some NMS cases due to atypical neuroleptics in the literature. As far as we know in the literature only two NMS cases due to risperidone treatment were reported in children. We think that atypical neuroleptics will be extensively used in children in the future and the clinicians especially the pediatricians must be familiar to NMS and its differential diagnosis.

We report this case in order to underline that neuroleptic malignant syndrome may be misdiagnosed as status epilepticus in children when EEG monitoring is unavailable. When a child is admitted to the emergency department because of unconsciousness muscular rigidity, diaphoresis, hypertermia and hypotension; neuroleptic drug use must surely be asked. Furthermore this is the third neuroleptic malignant syndrome case due to risperidone treatment in children. Early diagnosis and proper treatment of NMS may decrease the mortality rates significantly.

References
1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, Revised fourth edition. Washington, DC: American Psychiatric Press; 2000.
2. Leibold J, Patel V, Hasan RA. Neuroleptic malignant syndrome associated with ziprasidone in an adolescent. Clin Ther 2004;26:1105-8.
3. Steingard R, Khan A, Gonzales A, Herzog D. Neuroleptic malignant syndrome: review of experience with children and adolescents. J Child Adolesc Psychopharmacol 1992;2:183-98.
4. Gertz HJ, Schmidt LG. Low melatonin content of substantia nigra in a case of neuroleptic malignant syndrome. Pharmaco psychiatry 1991;24:93-5.
5. Ballard C, Grace J, Mckeith J, Holmes C. Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer’s disease. Lancet 1998;351:1032.
6. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77:185-202.
7. Srivastava A, Borkar HA, Chandak S. Olanzapine-induced neuroleptic malignant syndrome in a patient with paranoid schizophrenia. Psychiatry Clin Neurosci 2009;63:119-21.
8. Chungh DS, Kim BN, Cho SC. Neuroleptic malignant syndrome due to three atypical antipsychotics in a child. J Psychopharmacol 2005;19:422-5.
9. Vurucu S, Congologlu A, Altun D, et al. Neuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndrome J Natl Med Assoc 2009; 101:273-5.
